Acumen Pharmaceuticals Stock Debt To Equity
| ABOS Stock | USD 1.73 0.08 4.42% |
Fundamental analysis of Acumen Pharmaceuticals allows traders to better anticipate movements in Acumen Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Acumen Pharmaceuticals Company Debt To Equity Analysis
Acumen Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Acumen Pharmaceuticals has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The debt to equity for all United States stocks is 100.0% higher than that of the company.
Acumen Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Acumen Fundamentals
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 4.85 M | ||||
| Shares Outstanding | 60.57 M | ||||
| Shares Owned By Insiders | 7.03 % | ||||
| Shares Owned By Institutions | 66.58 % | ||||
| Number Of Shares Shorted | 1.37 M | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (124.21 M) | ||||
| EBITDA | (98.08 M) | ||||
| Net Income | (102.33 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 29.7 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 3.03 X | ||||
| Cash Flow From Operations | (86.22 M) | ||||
| Short Ratio | 3.13 X | ||||
| Earnings Per Share | (2.27) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 6.75 | ||||
| Number Of Employees | 61 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 109.64 M | ||||
| Total Asset | 238.99 M | ||||
| Retained Earnings | (325.13 M) | ||||
| Working Capital | 150.7 M | ||||
| Net Asset | 238.99 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.